Figure 5
(A) MM.1S cells were injected i.v. into NSG mice n=6. One-week post-injection, mice were randomized into two groups of n=3 and treated with vehicle or TIR-199 5 mg/kg i.p. daily for four consecutive days. One-week post-treatment, the mice were killed, and formalin-fixed femur bones were imaged using μCT. (B) Representative μCT image is shown post-μCT the trabecular number (C), the trabecular separation (D), and percentage of bone volume over total volume (E) were quantified for distal and proximal femurs. P-value shown for vehicle versus TIR-199 treatment and derived using t test. Data represented as mean ± SD, from n=6 femurs combining distal and proximal regions’ analyses for each.
Low-dose TIR-199 delays myeloma-mediated bone degeneration

(A) MM.1S cells were injected i.v. into NSG mice n=6. One-week post-injection, mice were randomized into two groups of n=3 and treated with vehicle or TIR-199 5 mg/kg i.p. daily for four consecutive days. One-week post-treatment, the mice were killed, and formalin-fixed femur bones were imaged using μCT. (B) Representative μCT image is shown post-μCT the trabecular number (C), the trabecular separation (D), and percentage of bone volume over total volume (E) were quantified for distal and proximal femurs. P-value shown for vehicle versus TIR-199 treatment and derived using t test. Data represented as mean ± SD, from n=6 femurs combining distal and proximal regions’ analyses for each.

Close Modal

or Create an Account

Close Modal
Close Modal